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Short Summary 25 
The hazard of PID increased significantly with the number of repeat chlamydia diagnoses among 26 
U.S. Army females. 27 




Background: In the U.S. military, chlamydia is the mostly commonly diagnosed bacterial 30 
sexually transmitted infection and the rates of pelvic inflammatory disease (PID) have remained 31 
high since the early 2000s.  32 
Methods: The relationship between the number of chlamydia diagnoses and risk of PID was 33 
investigated in a retrospective cohort analysis, among chlamydia cases in the U.S. Army during 34 
2006-2012.  Cox regression model was used to estimate hazard ratios (HR) for associations 35 
between the number of repeat chlamydia diagnoses and PID. 36 
Results: The study population comprised 33,176 females with chlamydia diagnosis.  Of these, 37 
25,098 (75%) were diagnosed only once (“non-repeaters”).  By comparison, 6,282 (19%), 1,435 38 
(4%), and 361 (1%) women had one, two, and three repeat chlamydia diagnoses, respectively.  39 
Among these four groups, 1,111, 325, 72, and 25 PID diagnoses were noted.  According to the 40 
Cox regression analysis, for every additional diagnosis of chlamydia, the risk of PID increased 41 
by 28% (95% CI = 19%, 38%) compared to females with a single diagnosis or “non-repeaters”.  42 
Moreover, the corresponding adjusted HR of 1.28, 1.35, and 1.97 represented a significantly 43 
greater risk for PID among the three “repeater” groups compared to “non-repeaters”. 44 
Conclusions: We found an increased risk of PID among U.S. Army females with repeat 45 
chlamydia diagnoses and the characterization of a dose-response relationship.  These findings 46 
reinforce the notion that early diagnosis and treatment of chlamydia is necessary to avoid 47 
subsequent PID and associated morbidity.  48 
Keywords: Pelvic inflammatory disease; chlamydia; military; STI; surveillance 49 
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Pelvic inflammatory disease (PID) is an infection of the upper female reproductive tract.1  51 
This serious, but treatable infection, can lead to complications such as ectopic pregnancy, tubal 52 
factor infertility, and chronic pelvic pain.2  Although the rates of PID have decreased over the 53 
past decade in the U.S., it still represents a significant health problem among women of 54 
reproductive age.3  Among the U.S. Army females, PID is also commonly diagnosed, with an 55 
estimated rate of ~11 PID cases per 1,000 person-years during 2002­2011.4 56 
Chlamydia trachomatis infection is an important risk factor for the development of PID, 57 
but its risk varies considerably.5  For example, Hillis et al.6 reported that the odds ratios of PID 58 
were 4.0 and 6.4 among 11,000 Wisconsin women with two versus three or more chlamydia 59 
infections, respectively.  In contrast, Davies et al.7 recently reported that among Canadian 60 
women the risk of PID after the first and the second repeat chlamydia infections was 1.2 and 1.3 61 
compared to those with one infection, respectively.  A plausible explanation for these differences 62 
may be due to the clinical diagnosis of PID is imprecise and challenge, with no a gold standard 63 
diagnostic test.1,8    64 
Since 2000, the U.S. Army has reported that chlamydia is the most commonly diagnosed 65 
bacterial sexually transmitted infection [STI].9  However, the risk of PID after having repeated 66 
chlamydia infections has not been studied to date.  Therefore, the aim of this study was to 67 
determine the relationship between the number of chlamydia diagnoses and hazard of PID 68 
among female military personnel.  To reach that aim, we conducted a retrospective cohort 69 





Study Design and Population 73 
Data were extracted from the DMSS, a large relational database that serves as the 74 
medical surveillance system for the U.S. Armed Forces since the 1990s.10  The DMSS collects 75 
information on demographics, medical encounters, immunizations, laboratory results, and 76 
deployments among personnel from the first day of entry until their departure from service.  The 77 
study population included all U.S. Army females aged 17­40 years, who were on active duty for 78 
any timeframe between 1 January 2006 and 31 December 2012, and who had at least one 79 
chlamydia diagnosis while in service.  The “chlamydia case” definition was based on the 80 
International Classification of Diseases, 9th version (ICD-9) diagnostic codes 099.41 or 099.5x 81 
in either the first or second position of an inpatient or outpatient medical record.  Women with a 82 
diagnosis of chlamydia, PID (614.9), infertility (628.4), pregnancy (V22.2), or gonorrhea 83 
(098.0x, 098.1x, or 098.8x) prior to 1 January 2006 were excluded.  Pregnant females were 84 
excluded to ensure homogeneity in terms of sexual risk in our population as risky behavior 85 
would probably be minimized during pregnancy by female service members in accordance with 86 
medical advice.   87 
Consequently, medical encounter records from all chlamydia cases were reviewed to 88 
determine the number of repeat chlamydia diagnoses (e.g. “repeaters”) since the first date of 89 
diagnosis until they reached one of the following censoring events: (1) a diagnosis of PID (list of 90 
ICD-9 codes is shown as a footnote in Table 2); (2) end of the study period; or (3) termination of 91 
service.  A repeat chlamydia diagnosis was defined as a diagnosis that occurred > 30 days from a 92 
prior positive chlamydia test.  Although this timeframe varies from study to study, a period of 30 93 
days has been most often used in epidemiologic assessments to avoid duplication of diagnosis for 94 
a single episode.11, 12  Besides, it is based on the evidence that nucleic acid amplification testing 95 
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can detect residual C. trachomatis nucleic acid for up to three weeks post-treatment13 and 96 
follows the U.S. Centers for Disease Control and Prevention (CDC) guidelines to report a 97 
positive chlamydia laboratory as a new infection.14 98 
 In addition to reviewing medical encounter data, for each chlamydia case detected during 99 
the study period, we extracted data from the DMSS, with respect to socio-demographic and 100 
military specific variables.  These variables included: (1) age (in years), (2) race/ethnicity (white, 101 
African-American, Hispanic, and other), (3) education (high school, college or higher), (4) 102 
marital status (single, married, and other), and (5) military rank (officer, enlisted).  103 
Statistical Analysis 104 
The demographic characteristics of the study population were summarized using 105 
descriptive statistics (e.g., means for continuous data and frequencies for categorical data).  We 106 
used the Kaplan-Meier estimator to determine the cumulative incidence rate of PID by the end of 107 
follow-up after the first, second, and third time “repeaters.”  To compare Kaplan-Meier 108 
cumulative incidence curves of PID diagnosis, the log-rank test was used.  We applied a Cox 109 
proportional hazards regression model to study differences on the distribution of time to PID 110 
diagnosis by the number of repeat chlamydia diagnoses.  The proportional-hazards assumption 111 
was evaluated using the Schoenfeld’s global test.15  Due to the small number of women with 112 
more than three repeat chlamydia diagnoses during the study period, these were excluded from 113 
analysis.  Data were analyzed using Stata version 12 (Stata Corporation, College Station, TX). 114 
 115 
RESULTS  116 
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The study population comprised 33,176 female military personnel with a chlamydia 117 
diagnosis during 2006-2012.  Of these, the mean (standard deviation) age at initial chlamydia 118 
diagnosis was 21.9 (standard deviation [SD] = 3.7) years and the median follow-up time was 2.9 119 
years (interquartile range [IQR]: 1.5­4.7 years).  As shown in Table 1, 25,098 (75%) women 120 
were diagnosed with C. trachomatis only once (“non-repeaters”).  By comparison, 6,282 (19%), 121 
1,435 (4%), and 361 (1%) women had one, two, and three repeat chlamydia diagnoses, 122 
respectively.  Among the repeaters, highest burden was in females aged 20-24 years (52-53%), 123 
African-Americans (37-44%), those of single marital status (73-78%), those with high school 124 
education (93-97%), and those within the enlisted rank (91-95%).    125 
Among the 33,176 females, a total of 1,533 (5%) PID diagnoses were subsequently 126 
diagnosed with a median time to diagnosis of 9 months.  Results stratified by repeat chlamydia 127 
diagnosis (Table 2) indicate that among the 25,098 females without a repeat chlamydia 128 
diagnosis, there were 1,111 (4%) PID diagnoses.  In this “non-repeater” group, the median time 129 
to PID diagnosis was 13 months.  For “repeater” females with “one” repeat chlamydia diagnosis, 130 
325 (5%) out 6,282 had a diagnosis of PID, with a median time of 10 months.  For females with 131 
“two” repeat chlamydia diagnoses, 72 (5%) out 1,435 had a diagnosis of PID, with a median 132 
time to diagnosis of eight months.  In addition, for 361 females with “three” repeat chlamydia 133 
diagnoses, there were 25 (7%) PID diagnoses, with a median time to diagnosis of only one 134 
month. 135 
According to the Kaplan-Meier analysis, the cumulative incidence of PID increased in a 136 
dose-response relationship among chlamydia “repeaters,” from 6% for females with a single 137 
chlamydia diagnosis (“non-repeaters”) to 9%, 10%, and 11% for females with one, two, and 138 
three repeat chlamydia diagnoses, respectively (Table 2).  The relationship between the four 139 
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study groups and cumulative incidence proportion of PID (1-survival) is depicted in Figure 1.  140 
Clearly, we can observe that as the number of chlamydia diagnosis increased, the incidence of 141 
PID increased.  In addition, the results showed that cumulative risk curves were statistically 142 
significantly different by the log-rank test (P < 0.001).     143 
According to the Cox regression analysis, for every additional diagnosis of chlamydia, 144 
the hazard of PID increased by 28% (95% CI = 19%, 38%, P < 0.001) compared to females with 145 
a single diagnosis or “non-repeaters”.  After controlling for age in years, race/ethnicity, marital 146 
status, and military rank, the hazard for PID decreased to 22% (95 % CI = 13%, 32%, P < 0.001) 147 
per additional chlamydia diagnosis, but remained statistically significant.  When the number of 148 
repeat chlamydia diagnoses was treated as a categorical predictor, as shown in Table 2, analysis 149 
revealed that women with one (hazard ratio [HR] = 1.34), two (HR = 1.48), and three (HR = 150 
2.21) repeat chlamydia diagnoses were at a significantly greater hazard of a diagnosis of PID as 151 
compared with females with a single diagnosis.  Moreover, after controlling for the above 152 
potential confounders, the adjusted HRs showed significantly greater risk for PID among the 153 
three “repeater” groups compared to “non-repeaters.”  Based on the Schoenfeld’s global test, the 154 
proportional-hazards assumption was met in both univariate (P = 0.338) and multivariate (P = 155 
0.176) analysis. 156 
 157 
DISCUSSION 158 
In this retrospective cohort analysis of 33,000 U.S. Army females, we found that the 159 
hazard of PID increased in a dose-response relationship with each additional repeat chlamydia 160 
diagnosis.  This finding highlights the importance of repeat chlamydia as a predisposing factor 161 
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for the development of subsequent PID and associated morbidity.  Furthermore, our findings are 162 
consistent with previous studies conducted among civilian populations.7,16-18  163 
The characteristics of the study population were consistent with those reported in other 164 
military-based studies in the literature.9,19  That is, among U.S. Army females, most chlamydia 165 
diagnoses occur among those aged 17-24 years, African-Americans, single, and in junior enlisted 166 
military ranks.  In our study, the percentage of women with repeat chlamydia diagnosis (24%) 167 
was slightly higher to that estimated by Owings et al.,12 who reported that between 2010 and 168 
2014, 20% of 23,482 female service members in the U.S. military were chlamydia “repeaters”.  169 
Nonetheless, this difference may be due to differences in time periods.  According to military 170 
surveillance reports, there was a peak in the annual incidence rate for chlamydia in the 2008.20 171 
Our results also showed that the median time in months to PID diagnosis decreased by 172 
the number of chlamydia diagnoses.  Although this finding may have important public health 173 
implications in terms of screening, it is worth mentioning that using administrative health data 174 
like the DMSS, it is difficult to estimate exactly the time from chlamydia infection to PID 175 
diagnosis, because both, the exposure and outcome, are highly asymptomatic.  With this caveat 176 
in mind, our data suggests that it may be wise to reinforce primary prevention activities as 177 
counseling and education to prevent a subsequent PID diagnosis among chlamydia “repeaters” 178 
among U.S. Army females.    179 
To the best of our knowledge, this is the first study to report the cumulative effect of 180 
repeat chlamydia diagnosis on the risk of PID in the U.S. military, a young, highly mobile, and 181 
sexually active population.21  According to DMSS data, the risk of PID for every one additional 182 
diagnosis of chlamydia increased by 28%, although this percentage was attenuated, but remained 183 
10 
 
high (17%) when adjusted for demographic and military characteristics.  Due to the fact that this 184 
was an observational study, we are not able to clearly explain the reasons for the increased risk 185 
or demonstrate a causal relationship between repeat chlamydia and PID diagnosis.  However, we 186 
provide additional evidence on the impact of repeat chlamydia diagnoses on the risk of PID to 187 
the STI literature.    188 
In addition to the observed cumulative effect of repeat chlamydia on PID, we found that 189 
the hazard of PID increases with the number of diagnoses of chlamydia.  Although our hazard 190 
estimates cannot be directly compared with previous civilian studies because they vary in terms 191 
of methodology, study population, and case identification,6-8,16-18,22 the consensus is the same.  In 192 
other words, there is an increasing risk of PID after repeat chlamydia diagnoses.  Despite these 193 
differences, the adjusted HRs of PID were similar to those reported by the largest published 194 
cohort of chlamydia and PID conducted to date.7  In that study, conducted in Canada among 195 
73,883 women aged 12-24 years during 1992-1996, the risk of PID after one and two repeat 196 
chlamydia diagnoses was 17% (95% CI = 6%, 30%) and 35% (95% CI = 4%, 75%), 197 
respectively.    198 
Limitations 199 
This study has some limitations.  First, the DMSS does not collect data on vaginal 200 
sanitary practices (e.g., douching), risky sexual behaviors (e.g., multiple risk partners), or use of 201 
oral or other forms of contraception.  Therefore, unmeasured confounders can affect the accuracy 202 
of our estimates.  Second, PID and chlamydia are often asymptomatic, therefore, the reported 203 
rates of PID might be underestimated and the number of women with repeat chlamydia 204 
diagnoses might be higher than analyzed.  Besides, a long-term asymptomatic chlamydia 205 
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infection increases the likelihood of developing PID compared with those that are diagnosed and 206 
treated quickly.  Third, the most widely used ICD-9 code (614.9) was applied to identify PID; 207 
however, some PID diagnoses might have been missed if a clinical diagnosis of PID was 208 
represented by other ICD-9 codes.  This may have resulted in an underestimation of the total 209 
number of PID cases in our study population.  Finally, the length of follow-up in our study (a 210 
median of three years) may not have captured all PID cases (e.g., PID could have occurred after 211 
the study period ended).  Therefore, this could have resulted in an underestimation of the true 212 
incidence of PID.  However, its effect is difficult to judge because each year ~10,000 new 213 
women enter and leave the U.S. Army.23   214 
Notwithstanding our limitations, this study included a large number of women, which 215 
increases the statistical precision of the parameter estimates.  Furthermore, all eligible female 216 
service members with a chlamydia diagnosis during the study period were selected, thus, the risk 217 
of selection bias was minimized.  As well, this is the first investigation reporting the time 218 
intervals between repeat chlamydia diagnoses and a subsequent diagnosis of PID, as well as the 219 
cumulative effect of repeat chlamydia on PID.  With the data presented, we feel that our findings 220 
contribute an additional measurable evidence on the role that chlamydia plays as a risk factor for 221 
PID. 222 
In conclusion, this study suggests that the hazard of a diagnosis of PID increased 223 
significantly with the number of repeat chlamydia diagnoses among U.S. Army females and this 224 
relationship was found to be characterized by a dose-response.  Additional research is needed to 225 
better understand the reasons for this increased risk for subsequent PID diagnosis.  These 226 
findings reinforce the notion that early diagnosis and treatment of chlamydia is necessary to 227 
avoid subsequent PID and associated morbidity.  It may be wise for military medical policy 228 
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makers to consider developing new preventive strategies that are effective in reducing the risk of 229 
PID among chlamydia “repeaters,” a targeted sub-group for further STI research in the U.S. 230 
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Women with  
two repeat CT  
diagnoses 
n (%) 
Women with  
three repeat CT 
diagnoses 
n (%) 
No. of women 33,176 (100) 25,098 (75)  6,282 (19) 1,435 (4) 361(1) 
Age group (years)      
   17-19 9,103 (27) 6,144 (24) 2,150 (34) 573 (40) 146 (40) 
   20-24 18,103 (54) 13,858 (55) 3,311 (53) 742 (52) 192 (53) 
   25-40 6,060 (19) 5,096 (21) 821 (13) 120 (8) 23 (7) 
Race/ethnicity      
   White 13,604 (42) 10,733 (43) 2,308 (37) 454 (32) 109 (31) 
   African-American 10,871 (33) 7,836 (32) 2,281 (37) 597 (42) 157 (44) 
   Hispanic 4,540 (14) 3,434 (14) 885 (14) 181 (13) 40 (11) 
   Other± 3,616 (11) 2,683 (11) 703 (11) 183 (13) 47 (13) 
Marital status      
   Single 23,295 (70) 17,311 (69) 4,601 (73) 1,103 (77) 280 (78) 
   Married 7,942 (24) 6,218 (25) 1,374 (22) 280 (19) 70 (19) 
   Other§ 1,925 (6) 1,557 (6) 305 (5) 52 (4) 11 (3) 
Education      
   High school 29,475 (90) 22,044 (89) 5,721 (93) 1,368 (97) 342 (97) 
   College or higher 3,108 (10) 2,598 (11) 450 (7) 48 (3) 12 (3) 
Military rank      
   Enlisted 28,695 (86) 21,318 (85) 5,684 (91) 1,351 (94) 342 (95) 
   Officers 4,481 (14) 3,780 (15) 598 (9) 84 (6) 19 (5) 
Note: CT, chlamydia.    319 
±Other race/ethnicity: American Indian/Alaskan Native, Asian/Pacific Islander, or other.  320 
§Other marital status: divorced, separated, widowed, or other. 321 
  322 
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TABLE 2.  Cumulative incidence rates and hazard ratios for pelvic inflammatory disease by the number of repeat chlamydia diagnoses. 323 
 324 
 Women  
with PID 
n/N 
Median  Cumulative  Cox Regression analysis  
Feature Follow-up time years 
incidence rate 
% (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI)¶  
Women without repeat diagnosis 1,111/25,098 3.10 6.54 (6.11, 6.99) Ref. Ref. 
Women with one repeat diagnosis 325/6,282 2.36 9.35 (7.71, 11.33) 1.34 (1.19, 1.52)a 1.28 (1.13, 1.45)a 
Women with two repeat diagnoses 72/1,435 1.86 10.38 (7.68, 13.96) 1.48 (1.17, 1.88)b 1.35 (1.06, 1.72)b 
Women with three repeat diagnoses 25/361 1.55 11.05 (6.84, 17.58) 2.21 (1.48, 3.28)a 1.97 (1.31, 2.96)b 
Note: PID, pelvic inflammatory disease (ICD-9 codes 098.10, 098.16, 098.17, 098.19, 098.86, 614.0, 614.2, 614.3, 614.5, 614.8, 614.9, 615.0, 615.9); p-y, person-years; 325 
CI, confidence interval; HR, hazard ratio; Ref., reference for HR calculation. 326 
¶Adjusted for age (in years), race/ethnicity, marital status, and military rank. 327 
aP < 0.001  328 
bP < 0.05  329 
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FIGURE 1.  Cumulative incidence of pelvic inflammatory disease by the number of repeat chlamydia diagnoses using the Kaplan-Meier 330 
method. 331 
 332 
 333 
 334 
